Advertisement
Organisation › Details
Kymera Therapeutics Inc. (Nasdaq: KYMR)
Kymera Therapeutics is a biotechnology company pioneering a transformative new approach to treating previously untreatable diseases. The company is advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade dysregulated, disease-causing proteins. Powered by Pegasus™, a game-changing integrated degradation platform, Kymera is accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. *
Start | 2017-10-31 existent | |
Industry | protein degradation drug | |
Street | 200 Arsenal Yards Blvd. Suite 230 | |
City | 02472 Watertown, MA | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Vertex Pharmaceuticals Inc.. (5/15/19). "Press Release: Vertex and Kymera Therapeutics Establish Strategic Collaboration to Discover and Develop Targeted Protein Degradation Medicines for Serious Diseases". Boston, MA & Cambridge, MA. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Kymera Therapeutics Inc. (Nasdaq: KYMR)
- [1] Kymera Therapeutics Inc.. (7/9/20). "Press Release: Kymera Therapeutics and Sanofi Enter into Strategic Partnership to Advance Novel Protein Degrader Therapies to Advance Novel Protein Degrader Therapies to Patients". Cambridge, MA....
- [2] Kintai Therapeutics, Inc.. (9/11/19). "Press Release: Kintai Therapeutics Appoints Senior Executive Dr. Mark E. Nuttall as Chief Business Officer". Cambridge, MA....
- [3] Kymera Therapeutics Inc.. (11/13/18). "Press Release: Kymera Therapeutics Announces $65 Million Series B Financing to Advance Pipeline of Targeted Protein Degraders in Oncology and Immunology". Cambridge, MA....
- [4] Kymera Therapeutics Inc.. (2/16/18). "Press Release: Kymera Therapeutics Appoints Industry Veteran Mark E. Nuttall, Ph.D., as Chief Business Officer. Don W. Nicholson, Ph.D. joins Board of Directors". Cambridge, MA....
- [5] Kymera Therapeutics LLC. (10/30/17). "Press Release: Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies". Cambridge, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top